Brandon G Busbee

Summary

Publications

  1. ncbi Incremental cost-effectiveness of initial cataract surgery
    Brandon G Busbee
    Center for Evidence-Based Health Care Economics, Wills Eye Hospital, Jefferson Medical College, Philadelphia, PA, USA
    Ophthalmology 109:606-12; discussion 612-3. 2002
  2. ncbi Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
    Brandon G Busbee
    Tennessee Retina, Nashville, Tennessee Electronic address
    Ophthalmology 120:1046-56. 2013
  3. ncbi Cost-effectiveness of ocular interventions
    Brandon G Busbee
    The Center for Evidence Based Health Care Economics, Retina Vascular Unit, Cataract and Primary Eye Care Service, Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Curr Opin Ophthalmol 14:132-8. 2003
  4. ncbi Endophthalmitis: a reappraisal of incidence and treatment
    Brandon G Busbee
    Retina Vitreous Associates, Nashville, Tennessee 37203, USA
    Curr Opin Ophthalmol 17:286-91. 2006
  5. ncbi Cost-utility analysis of cataract surgery in the second eye
    Brandon G Busbee
    Center for Evidence Based Health Care Economics, Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Ophthalmology 110:2310-7. 2003
  6. ncbi Advances in knowledge and treatment: an update on endophthalmitis
    Brandon G Busbee
    The Retina Service, New England Eye Center Tufts University and Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Curr Opin Ophthalmol 15:232-7. 2004
  7. ncbi Changing trends in the microbiologic aspects of postcataract endophthalmitis
    Franco M Recchia
    Division of Vitreoretinal Diseases and Surgery, Vanderbilt Eye Institute, Nashville, Tenn 37232, USA
    Arch Ophthalmol 123:341-6. 2005
  8. ncbi Update on treatment strategies for bleb-associated endophthalmitis
    Brandon G Busbee
    Retina Vitreous Associates, Nashville, Tennessee, USA
    Curr Opin Ophthalmol 16:170-4. 2005
  9. ncbi Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Retina 29:1310-3. 2009
  10. ncbi Bleb-associated endophthalmitis: clinical characteristics and visual outcomes
    Brandon G Busbee
    Retina Service, New England Eye Center, Boston, USA
    Ophthalmology 111:1495-503; discussion 1503. 2004

Collaborators

Detail Information

Publications13

  1. ncbi Incremental cost-effectiveness of initial cataract surgery
    Brandon G Busbee
    Center for Evidence-Based Health Care Economics, Wills Eye Hospital, Jefferson Medical College, Philadelphia, PA, USA
    Ophthalmology 109:606-12; discussion 612-3. 2002
    ..This information, incorporating patient preferences into evidenced-based medicine, will play an increasingly important role in the evaluation of health care in the future...
  2. ncbi Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
    Brandon G Busbee
    Tennessee Retina, Nashville, Tennessee Electronic address
    Ophthalmology 120:1046-56. 2013
    ..5 mg and 2.0 mg administered monthly and on an as-needed (PRN) basis in treatment-naïve patients with subfoveal neovascular age-related macular degeneration (wet AMD)...
  3. ncbi Cost-effectiveness of ocular interventions
    Brandon G Busbee
    The Center for Evidence Based Health Care Economics, Retina Vascular Unit, Cataract and Primary Eye Care Service, Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Curr Opin Ophthalmol 14:132-8. 2003
    ....
  4. ncbi Endophthalmitis: a reappraisal of incidence and treatment
    Brandon G Busbee
    Retina Vitreous Associates, Nashville, Tennessee 37203, USA
    Curr Opin Ophthalmol 17:286-91. 2006
    ..The current publications that address either the incidence or treatment of endophthalmitis are reviewed...
  5. ncbi Cost-utility analysis of cataract surgery in the second eye
    Brandon G Busbee
    Center for Evidence Based Health Care Economics, Wills Eye Hospital, Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Ophthalmology 110:2310-7. 2003
    ..To perform a reference case cost-utility analysis of second-eye cataract surgery by using the current literature on cataract outcomes and complications...
  6. ncbi Advances in knowledge and treatment: an update on endophthalmitis
    Brandon G Busbee
    The Retina Service, New England Eye Center Tufts University and Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Curr Opin Ophthalmol 15:232-7. 2004
    ..Because complete elimination of postsurgical endophthalmitis appears unattainable, strategies directed at optimal prevention, diagnosis, and management are constantly pursued...
  7. ncbi Changing trends in the microbiologic aspects of postcataract endophthalmitis
    Franco M Recchia
    Division of Vitreoretinal Diseases and Surgery, Vanderbilt Eye Institute, Nashville, Tenn 37232, USA
    Arch Ophthalmol 123:341-6. 2005
    ..To analyze the microbiologic spectrum and in vitro susceptibility profiles over the last 11 years of organisms isolated from the vitreous of patients with endophthalmitis following cataract surgery...
  8. ncbi Update on treatment strategies for bleb-associated endophthalmitis
    Brandon G Busbee
    Retina Vitreous Associates, Nashville, Tennessee, USA
    Curr Opin Ophthalmol 16:170-4. 2005
    ..SUMMARY: More options are now available to treat bleb-associated endophthalmitis. No one treatment paradigm is definitively superior in producing desired visual outcomes...
  9. ncbi Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts 02114, USA
    Retina 29:1310-3. 2009
    ..To assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E(2) in patients treated with NSAIDs before vitrectomy...
  10. ncbi Bleb-associated endophthalmitis: clinical characteristics and visual outcomes
    Brandon G Busbee
    Retina Service, New England Eye Center, Boston, USA
    Ophthalmology 111:1495-503; discussion 1503. 2004
    ..09). CONCLUSIONS: Bleb-associated endophthalmitis causes significant visual morbidity. Patients with culture-negative BAE and patients treated with prompt PPV may achieve better visual outcome...
  11. ncbi Overview of ocular anesthesia: past and present
    Juanita S Bryant
    New England Eye Center Boston, Massachusetts, USA
    Curr Opin Ophthalmol 22:180-4. 2011
    ..Many choices of ocular anesthetic techniques are available to the ophthalmologist. This study reviews currently used techniques of topical, subconjunctival and regional block anesthesia used in ophthalmic procedures...
  12. ncbi CME review: A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization
    Brandon G Busbee
    Center for Value-Based Medicine, and Department of Ophthalmology, Tufts New England Medical Center, USA
    Retina 23:279-87; ; quiz 443-4. 2003
    ..CONCLUSION: Laser photocoagulation for extrafoveal choroidal neovascularization associated with age-related macular degeneration appears to be cost-effective when compared with interventions across multiple medical specialties...
  13. ncbi Value-based medicine: a new paradigm to evaluate treatments for vitreoretinal diseases and other medical interventions
    Brandon G Busbee
    Ophthalmic Consultants of Boston, MA 02114, USA
    Int Ophthalmol Clin 44:155-72. 2004